Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

The study adds important data about how people with hematologic malignancies are affected by COVID-19 infection. | Image credit: Tyler Olson -stock.adobe.com
COVID-19 Risk Remains High for Patients With Hematologic Malignancies

September 10th 2025

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

Patients with an inflammatory transcriptome profile at 3 months had a greater risk of an infection. | Image credit: Saiful52 - stock.adobe.com
Immune Profiling May Help Gauge Infection Risk in Patients With CLL

August 31st 2025

Real-world outcomes of venetoclax treatment were similar to those seen in clinical trials in patients with chronic lymphocytic leukemia | Image Credit: tippapatt - stock.adobe.com
Real-World Data Support Safety, Efficacy of Venetoclax for CLL

August 29th 2025

It was difficult to generate strong conclusions from the existing data due to the “sparse and heterogeneous” nature of the cardiovascular data reported in the trials. | Image credit: Tima - stock.adobe.com
Age, BTKi Use May Contribute to Cardiovascular Risk in CLL

August 27th 2025

The new research points to the potential of AP-1 and stromal interactions as promising targets to overcome resistance and improve outcomes in CLL. | Image credit: jarun011 - stock.adobe.com
AP-1 as a Therapeutic Focus in CLL

August 26th 2025

More News

money and stethoscope | Image Credit: © pla2na - stock.adobe.com
October 17th 2024

Zanubrutinib Not Cost-Effective in China Against Fixed-Duration R-Bendamustine in 1L CLL

AJMC Contributor
The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R-bendamustine) for these patients.
Skin Cancer Potential | Image Credit: © Monstar Studio-stock.adobe.com
October 16th 2024

Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis

Karen Jacobson-Sive
Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma.
Acalabrutinib demonstrates superior safety over ibrutinib in the treatment of CLL/SLL | image credit: sovova - stock.adobe.com
October 9th 2024

Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL

Jared Kaltwasser
A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.
diagnosis leukemia | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com
October 4th 2024

Real-World Data Support TKI Discontinuation After CP-CML Remission

Jared Kaltwasser
Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite discontinuing therapy.
CAR T cell | Image Credit: © Christoph Burgstedt - stock.adobe.com
October 3rd 2024

B-Cell Activating Factor Receptor CAR T Therapy Holds Promise for CLL

Karen Jacobson-Sive
B-cell activating factor receptor chimeric antigen receptor (CAR) T-cell therapy caused cytotoxic effects on all chronic lymphocytic leukemia (CLL) cell lines.
Clinical research | Image Credit: © peshkova-stock.adobe.com
September 27th 2024

Venetoclax Plus Rituximab Supports Immune Recovery in CLL

Kimberly Rath, PharmD
Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab.
Understanding genetic alterations in CLL could improve personalized medicine strategies | image credit: Shuo - stock.adobe.com
September 24th 2024

Exploring the Impact of TP53 Alterations on miR-34a and NOTCH1 in CLL

Kimberly Rath, PharmD
New study provides insights into the relationship between TP53, miR-34a, and NOTCH1 in CLL cells.
Doctor consulting with a patient | Image Credit: © bnenin - stock.adobe.com
September 19th 2024

Gaps Apparent in Physicians’ Knowledge of CLL, MCL

Nameera Temkar, MD
Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL).
Image credit: Laszlo-stock.adobe.com
September 13th 2024

Predicting Survival in CLL: The Power of Measurable Residual Disease

Kimberly Rath, PharmD
Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis.
Doctor holding heart | Image Credit: © Pana Studio - stock.adobe.com
September 12th 2024

Acalabrutinib vs Ibrutinib: Real-World Insights Into Safety Differences for Patients With CLL

Kimberly Rath, PharmD
The latest study findings suggest that acalabrutinib may be a safer option than ibrutinib for patients with chronic lymphocytic leukemia, offering a lower risk of serious cardiovascular and infection-related adverse events.
red blood cells model CLL | image credit: digitalpochi - stock.adobe.com
September 4th 2024

B-Cell Activating Factor Levels May Predict Reduced Risk of CLL, Study Finds

Kimberly Rath, PharmD
A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.
Skin cancer is a dangerous morbidity risk in patients with CLL | image credit: Ocskay Mark - stock.adobe.com
August 26th 2024

Study Implicates AXL in Skin Cancer Development in CLL

Jared Kaltwasser
The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.
CLL cells | image credit: Arif Biswas - stock.adobe.com
August 19th 2024

Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

Nameera Temkar, MD
A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.
CLL | Image Credit: Saiful52-stock.adobe.com
August 16th 2024

New Model Offers Indicators of Ibrutinib Response in CLL

Jared Kaltwasser
A mathematical model using pharmacodynamic parameters, including duration of hyperlymphocytosis, may help clinicians better predict patient responses to ibrutinib administered for chronic lymphocytic leukemia (CLL).
DNA helix inside blood drop | Image credit: Елена Бутусова - stock.adobe.com
August 12th 2024

NGS-Based Risk Stratification, Treatment Shows Cost-Effectiveness in CLL

AJMC Contributor
A Canadian study showed a high probability that using next-generation sequencing (NGS) for treatment sequencing based on risk stratification is cost-effective.
Precision medicine | Image Credit: leowolfert-stock.adobe.com
August 8th 2024

Opportunities Remain for Expanding Precision Medicine in CLL

AJMC Contributor
As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.
biomarker word cloud | Image Credit: laufer-stock.adobe.com
August 4th 2024

Biomarker Incorporated Into Novel CLL Outcome Prediction Model

Gayle Turim Dickstein
Researchers believe that in their revised 4-factor model to predict patient outcomes in chronic lymphocytic leukemia (CLL), CD49d tops lactate dehydrogenase.
concept of a genetic mutation | Image Credit: © lucadp - stock.adobe.com
August 1st 2024

Co-Occurrence of del(6q), RPS15 May Drive Poor Prognosis in CLL

AJMC Contributor
The findings support previous research suggesting that worse prognosis in patients with del(6q) is not solely a result of genomic instability or presence of multiple genetic alterations.
Clinical link research | Image Credit: sdecoret - stock.adobe.com
July 27th 2024

MRD, Clinical Outcomes Linked in Chronic Leukemia

Gayle Turim Dickstein
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
cancer treatment | Image Credit: tashatuvango-stock.adobe.com
July 20th 2024

Study Reveals Top Treatment Priorities in Patients With CLL

Kimberly Rath, PharmD
Researchers of a new study explore what areas of chronic lymphocytic leukemia (CLL) treatment and care are important to patients and identify key areas for improvement.
Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, CLL Society
July 16th 2024

Advancements in CLL: A Conversation With Dr Brian Koffman

Brooke McCormick Maggie L. Shaw
In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.
CLL cells | Image credit: Laszlo - stock.adobe.com
July 13th 2024

Study Finds Pirtobrutinib Associated With Improved Outcomes vs Venetoclax in Relapsed CLL

Karen Jacobson-Sive
Pirtobrutinib led to improved outcomes compared with venetoclax in patients with relapsed chronic lymphocytic leukemia (CLL) following covalent Bruton tyrosine kinase inhibitor therapy.
A panel of 4 experts on CLL
July 12th 2024

Factors Influencing Choice of Second-Generation BTKi Monotherapy

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
Specialists discuss factors influencing the choices of second-generation BTK monotherapy.
A panel of 4 experts on CLL
July 12th 2024

Evaluating Value of BTK Inhibitors in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
Experts evaluate the value of BTK inhibitors in CLL treatment.
zanubrutinib | Image Credit: molekuul.be-stock.adobe.com
July 10th 2024

Zanubrutinib Safer Than Ibrutinib in Patients With B-Cell Malignancies

Karen Jacobson-Sive
A post-hoc analysis showed that zanubrutinib resulted in fewer adverse events compared with ibrutinib.
genetic mutation testing | Image Credit: JohanSwanepoel-stock.adobe.com
July 6th 2024

Report Recommends Strategy to Identify CLL in Patient With Posterior Uveitis

Jared Kaltwasser
It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly.
Asian patient | Image Credit: kapinon-stock.adobe.com
July 2nd 2024

VenR Achieves Strong Results in Japanese CLL/SLL Cohort

Jared Kaltwasser
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are rare in Japan, but a new report affirms the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) (VenR) in this population.
leukemia word map | Image Credit: dizain-stock.adobe.com
Published: June 28th 2024 | Updated: June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser
Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.
A panel of 4 experts on CLL
June 28th 2024

CLL Treatment Landscape: Overview of BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.
A panel of 4 experts on CLL
June 28th 2024

Recent Trends and Innovations in the Management of CLL

Ryan Haumschild, PharmD, MS, MBA Roy Beveridge, MD Brian T. Hill, MD, PhD Adam S. Kittai, MD
Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.
<123456>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo